OCT valuable for evaluating treatment effects in CNV
April 15th 2006Miami?Optical coherence tomography (OCT) can be a valuable tool for evaluating the status of choroidal neovascularization (CNV) in patients with wet age-related macular degeneration (AMD), particularly when new drugs are being used to treat the disease, said Philip J. Rosenfeld, MD, PhD, associate professor of ophthalmology, Bascom Palmer Eye Institute, Miami.
Anecortave acetate found safe, effective in AMD
April 15th 2006New York?Anecortave acetate (Retaane 15 mg suspension, Alcon Laboratories) seems to be safe and effective for the treatment of exudative age-related macular degeneration (AMD) compared with photodynamic therapy (PDT) with verteporfin for injection (Visudyne, Novartis Ophthal-mics/QLT Inc.).
Intravitreal implant shows promise in DME, vein occlusion
April 15th 2006Durham, NC?The Retisert implant (Bausch & Lomb), a nonbiogradable device containing fluocinolone acetonide, is approved for the treatment of posterior uveitis and seems promising in the treatment of diabetic macular edema (DME) and vein occlusion in clinical trials, according to Glenn Jaffe, MD.
New treatment may usher new era for AMD patients
April 15th 2006Winter Haven, FL?A number of new pharmacologic options for exudative age-related macular degeneration (AMD), mostly designed to block different steps in the angiogenic cascade, are in various stages of development and testing, and some may one day be shown to improve outcomes, said Michael J. Tolentino, MD, director of clinical research, Center for Retina and Macular Disease, Winter Haven, FL.
Nonsurgical methods of vision corrrection should be option
April 15th 2006Minneapolis?Refractive surgeons should incorporate rather than dismiss corneal refractive therapy (orthokeratology) and contact lens fitting because those techniques can have a synergistic benefit rather than play a competitive role in a refractive surgery practice, according to David R. Hardten, MD.
Vision screening standardization recommended
April 15th 2006Portland, OR?Mass vision screening of school-age children was first recommended in 1983. At that time there was not a large population of children of preschool age, a situation that has changed markedly since then because today many more 3- and 4-year-olds are in a preschool setting. However, there is still no standardization in vision screening.
Torsional phaco likely to change cataract surgery landscape
April 15th 2006Dorado, Puerto Rico?Torsional phacoemulsification offers cataract surgeons a new way to remove nucleus material more efficiently and safely than traditional longitudinal ultrasound, reported Richard J. Mackool, MD, who spoke during the Current Concepts in Ophthalmology meeting here.
Screenings for amblyopia should be standardized
April 15th 2006Madison, WI - Uniform testing and reporting criteria are needed toidentify amblyogenic risk factors in children and prevent thedevelopment of amblyopia. Leslie W. France, CO, described theevidence base for the guidelines to detect amblyogenic riskfactors.
Retrospective single-surgeon study suggests ALT superior to SLT
April 1st 2006Calgary, Alberta, Canada?In a single-surgeon study of glaucoma patients with uncontrolled IOP on maximally tolerated medical therapy, argon laser trabeculoplasty (ALT) was associated with a greater IOP-lowering effect than selective laser trabeculoplasty (SLT), reported Bryce Ford, MD.
Telemedicine helpful tool for assessing diabetic retinopathy
April 1st 2006Baltimore?The problem of an increasingly large population of patients with diabetes has spawned a novel and sometimes controversial approach to management: consultation via telemedicine assessment. Ingrid Zimmer-Galler, MD, discussed this high-tech approach to care at the recent Current Concepts in Ophthalmology meeting.
Enhanced efficacy associated with early treatment of neovascular AMD
April 1st 2006Los Angeles?Building on results of a study demonstrating that treatment with pegaptanib sodium (Macugen, OSI/Eyetech Pharmaceuticals) helps preserve vision and limit progression in patients with wet age-related macular degeneration (AMD), a retrospective subgroup analysis has shown that early treatment may produce even better outcomes, according to Christine R. Gonzales, MD, assistant professor of ophthalmology, Jules Stein Eye Institute, University of Los Angeles.
Race may affect acuity outcomes of pars plana vitrectomy
April 1st 2006Jackson, MS?A study that compared the outcomes of pars plana vitrectomy performed to treat complications of proliferative diabetic retinopathy (PDR) based on racial differences among Caucasians, Choctaw Indians, and African Americans found that race might affect outcomes.
Investigational combination product yields similar bioequivalence of corticosteroid
April 1st 2006An investigational ophthalmic combination product containing tobramycin 0.3% and prednisolone acetate 1% seems to be bioequivalent to a marketed preparation of prednisolone acetate 1%, according to recently released results from a phase III trial.
Match patient with suitable ocular allergy drug criteria
April 1st 2006Carlsbad, CA?In his private practice here, Bill G. Bell, MD, has established a system by which he matches patients with what he hopes is the optimum ocular allergy therapy?especially important in southern California where "every month is allergy month."
Agent's activity profile targets ocular allergy symptoms
April 1st 2006Kansas City, MO?Olopatadine HCl (Patanol, Alcon Laboratories) offers a unique pharmacologic profile of activity that corresponds to its unsurpassed efficacy in the management of allergic conjunctivitis, according to the results from comparative studies published in the peer-reviewed literature, said Lanny J. Rosenwasser, MD.
Corticosteroid provides potent, safe ocular allergy control
April 1st 2006Experience from clinical trials and daily clinical practice indicate that loteprednol etabonate 0.2% (Alrex, Bausch & Lomb) is a valuable therapeutic option for both short- and longer-term management of allergic conjunctivitis, according to ophthalmologists who have studied and used this novel anti-inflammatory corticosteroid agent.